Treatment of Homozygous Familial Hypercholesterolemia With EvinacumabNovel Teaching Points [PDF]
CJC Open, 2022 Patients with homozygous familial hypercholesterolemia (HoFH) have extremely elevated levels of low-density lipoprotein cholesterol (LDL-C), with premature atherosclerosis and aortic valve disease.
Natasha Jeraj, BSc +3 more
doaj +3 more sources
Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia [PDF]
CPT: Pharmacometrics & Systems Pharmacology, 2021 Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH).
Xia Pu +5 more
doaj +3 more sources
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study [PDF]
Advances in TherapyHomozygous familial hypercholesterolemia (HoFH) is a severe rare genetic disorder characterized by elevated plasma low-density lipoprotein (LDL) cholesterol levels. Here, we report data from the Italian cohort of the Evinacumab Lipid Studies in Patients with Homozygous Familial Hypercholesterolemia (ELIPSE HoFH) trial.ELIPSE HoFH was conducted at 30 ...
Giuliana Fortunato +2 more
exaly +5 more sources
Evinacumab: Mechanism of action, clinical, and translational science
Clinical and Translational ScienceHomozygous familial hypercholesterolemia (HoFH) is a rare and serious genetic condition characterized by premature cardiovascular disease due to severely elevated low‐density lipoprotein cholesterol (LDL‐C).
Robert Dingman +4 more
doaj +3 more sources
Antibody-Based Therapeutics for Hypercholesterolemia [PDF]
Biologics: Targets & TherapyBrian Tomlinson,1 Paul Chan2 1Faculty of Medicine, Macau University of Science & Technology, Macau, 999078, People’s Republic of China; 2Division of Cardiology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei ...
Tomlinson B, Chan P
doaj +2 more sources
A Comprehensive Review of the Latest Approaches to Managing Hypercholesterolemia: A Comparative Analysis of Conventional and Novel Treatments: Part II [PDF]
PharmaceuticalsCardiovascular disease (CVD) remains the leading cause of mortality worldwide, with hypercholesterolemia identified as a major, but modifiable risk factor. This review serves as the second part of a comprehensive analysis of dyslipidemia management.
Narcisa Jianu +9 more
doaj +2 more sources
Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
International Journal of Cardiology. Cardiovascular Risk and Prevention, 2021 Stanisław Surma +2 more
doaj +4 more sources
Pharmaceuticals, 2022 Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) concentrations from birth and increased risk of premature atherosclerotic cardiovascular ...
Claudia Stefanutti +4 more
doaj +1 more source
Therapeutic Plasma Exchange and Evinacumab for Homozygous Familial Hypercholesterolemia. [PDF]
JACC Case RepHomozygous familial hypercholesterolemia (HoFH) is challenging to treat, requiring intensive lipid-lowering therapy often with novel therapies like evinacumab (angiopoietin-like 3 (ANGPLT3) inhibitor) and procedures like lipoprotein apheresis or therapeutic plasma exchange.A 47-year-old woman with HoFH and recurrent atherosclerotic cardiovascular ...
Raygani S +4 more
europepmc +3 more sources
Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia
Journal of Clinical Medicine, 2022 Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and triglycerides (TG) levels and, thus, is a potentially ...
Bożena Sosnowska +4 more
openaire +3 more sources